^
Association details:
| Biomarker: | PIK3CA H1047 |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
19P - PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
Published date:
05/23/2020
Excerpt:
PIK3CA hot-spot mutations in exon 9 (E542K, E545K-A-G, Q546E-K) and exon 20 (M1043I, H1047R-L-Y, G1049R-S)...PIK3CA mutation showed a favorable prognostic impact in the subgroup of patients owing to the PAM50 HER2-enriched subtype (n=232): 5-yr DFS 91.8% vs 76.1% for PIK3CA mutated and wild-type patients (log-rank p=0.049; HR 0.46 95% CI 0.21-1.02)....Within the HER2-enriched molecular subtype, PIK3CA mutated patients showed better DFS as compared to PIK3CA wild-type patients.
